Dubai, Tuesday 30 January 2018 17.35 CET
The United Arab Emirates (UAE) will now use deprexis MS, GAIA’s digital therapy software, to treat depression in multiple sclerosis (MS) patients.
Government officials made this announcement at the ongoing Arab Health Exhibition and Conference in Dubai, which runs until February 1, 2018. “It is great to leverage the latest scientific technologies to alleviate the suffering of patients,” said the UAE’s Assistant Undersecretary for Hospitals, H.E Dr Yousif Al Serkal.
GAIA is particularly proud of this milestone. “A lot of patients with multiple sclerosis suffer from depressive symptoms. With deprexis MS we offer an effective therapeutic option that has synergetic effects to modern MS drugs,” notes GAIA’s founder and CEO Dr. Mario Weiss.
Digital therapeutics like GAIA’s deprexis MS represents clinically trialled solutions with the same effect size as drugs shown to improve the quality of life of patients.